Your browser doesn't support javascript.
loading
Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.
Linfield, Debra T; Rothberg, Michael B; Pfoh, Elizabeth R; Noss, Ryan; Cassard, Lydia; Powers, Joseph C; Lipold, Laura; Martinez, Kathryn A.
Afiliação
  • Linfield DT; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
  • Rothberg MB; Cleveland Clinic Center for Value-Based Care Research, 9500 Euclid Avenue, Desk G10, Cleveland, OH, 44195, USA.
  • Pfoh ER; Cleveland Clinic Center for Value-Based Care Research, 9500 Euclid Avenue, Desk G10, Cleveland, OH, 44195, USA.
  • Noss R; Center for Personalized Genetic Healthcare, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Cassard L; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
  • Powers JC; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
  • Lipold L; Department of Family Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Martinez KA; Cleveland Clinic Center for Value-Based Care Research, 9500 Euclid Avenue, Desk G10, Cleveland, OH, 44195, USA. martink12@ccf.org.
Breast Cancer Res Treat ; 195(2): 153-160, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35842521
ABSTRACT

PURPOSE:

The United States Preventive Services Task Force recommends primary care physicians refer patients at high risk for BRCA1/2 mutations to genetic testing when appropriate. The objective of our study was to describe referrals for BRCA1/2 testing in a large integrated health system and to assess factors associated with referral.

METHODS:

This retrospective cohort study includes female patients between 18 and 50 years who had a primary care visit in the Cleveland Clinic Health System between 2010 and 2019. We used multivariable logistic regression to estimate differences in the odds of a woman being referred for BRCA1/2 testing by patient factors and referring physician specialty. We also assessed variation in referrals by physicians.

RESULTS:

Among 279,568 women, 5% were high risk. Of those, 22% were referred for testing. Black patients were significantly less likely to be referred than white patients (aOR 0.87; 95% CI 0.77, 0.98) and Jewish patients were more likely to be referred than non-Jewish patients (aOR 2.13; 95% CI 1.68, 2.70). Patients primarily managed by OB/GYN were significantly more likely to be referred than those cared for via Internal/Family Medicine (aOR 1.45; 95% CI 1.30, 1.61). Less than a quarter of primary care physicians ever referred a patient for testing.

CONCLUSION:

The majority of primary care patients at high risk for a BRCA1/2 mutation were not referred for testing, and over a decade, most physicians never referred a single patient. Internal/Family Medicine physicians, in particular, need support in identifying and referring women who could benefit from testing.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Médicos de Atenção Primária Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Female / Humans País/Região como assunto: America do norte Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Médicos de Atenção Primária Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Female / Humans País/Região como assunto: America do norte Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos